Daptomycin: pharmacology and clinical use

被引：39

作者：

Kosmidis, Christos ^{[1
]}

Levine, Donald P. ^{[1
]}

机构：

[1] Wayne State Univ, Univ Hlth Ctr, Dept Med, Detroit, MI 48201 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 04期

关键词：

daptomycin; Gram-positive infections; pharmacology; resistance; RESISTANT STAPHYLOCOCCUS-AUREUS; IN-VITRO ACTIVITIES; ACUTE-RENAL-FAILURE; ENTEROCOCCAL BACTEREMIA; COMPLICATED SKIN; REDUCED SUSCEPTIBILITY; BACTERICIDAL ACTIVITY; ANTIMICROBIAL AGENTS; VANCOMYCIN; EXPERIENCE;

D O I：

10.1517/14656561003598893

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Areas covered in this review: Literature from 1986 to present was reviewed for pharmacological, preclinical and clinical studies on daptomycin. What the reader will gain: The pharmacological properties, resistance mechanisms and clinical applications of daptomycin are discussed. Recommendations are offered on the use of this agent for the treatment of resistant Gram-positive infections. Take home message: Daptomycin is a reliable agent for the treatment of Gram-positive infections. It has been shown to be effective in bacteremia and endocarditis, as well as in soft-tissue infections caused by Gram-positive organisms. Its role in the treatment of bone and joint infections is not well-defined. Resistance is currently uncommon in clinical isolates. However, emergence of resistance during therapy is a concern. This may be prevented by use of higher doses.

引用

页码：615 / 625

页数：11

共 79 条

[1] Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection [J].

Alder, J ;

Li, TC ;

Yu, DH ;

Morton, L ;

Silverman, J ;

Zhang, XX ;

Critchley, I ;

Thorne, G .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3561-3566

[2]

[Anonymous], 47 ANN M INF DIS SOC

[3] Clinical Experience With Daptomycin in Patients With Orthopedic-Related Infections [J].

Antony, Suresh J. ;

Angelos, Erin ;

Stratton, Charles W. .

INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2006, 14 (03) :144-149

[4] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].

Arbeit, RD ;

Maki, D ;

Tally, FP ;

Campanaro, E ;

Eisenstein, BI .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681

[5] Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers [J].

Benvenuto, Mark ;

Benziger, David P. ;

Yankelev, Sara ;

Vigliani, Gloria .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3245-3249

[6] Cost-Effectiveness of Daptomycin versus Vancomycin and Gentamicin for Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia and/or Endocarditis [J].

Bhavnani, S. M. ;

Prakhya, A. ;

Hammel, J. P. ;

Ambrose, P. G. .

CLINICAL INFECTIOUS DISEASES, 2009, 49 (05) :691-698

[7] Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens [J].

Carpenter, CF ;

Chambers, HF .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (07) :994-1000

[8] Daptomycin dose-effect relationship against resistant gram-positive organisms [J].

Cha, R ;

Grucz, RG ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1598-1603

[9] Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection [J].

Chakraborty, Abhijit ;

Roy, Sandip ;

Loeffler, Juergen ;

Chaves, Ricardo L. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (01) :151-158

[10] In vitro activities of daptomycin, ciprofloxacin, and other antimicrobial agents against the cells and spores of clinical isolates of Bacillus species [J].

Citron, Diane M. ;

Appleman, Maria D. .

JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (10) :3814-3818

← 1 2 3 4 5 6 7 8 →